Hemangioblastoma

Hemangioblastoma is a benign (Grade 1) vascular tumor of the brain and spinal cord. It does not spread to other parts of the body, grows slowly, and most patients recover when it is completely removed. It is one of the most common tumors in the posterior-inferior region (cerebellum) of the brain in adults. It consists of supportive cells and abundant vascular structures. Some cases occur with a hereditary disease called Von Hippel-Lindau (VHL), in which patients may have multiple tumors. The prognosis is usually very good when the tumor is completely removed.

Symptoms vary depending on tumor location. In cerebellar location: unsteady gait, eye tremor, headache, nausea-vomiting, dizziness, and inability to coordinate movements. In spinal cord location: back or neck pain, arm-leg weakness, numbness, and loss of sensation. If the tumor secretes hormone causing elevated red blood cell count (polycythemia): facial flushing, headache, itching. In brainstem involvement, there may be swallowing and speech difficulty. Symptoms usually progress slowly (over months-years).

Diagnostic methods: 1) Contrast-enhanced MRI - typical appearance is a fluid-filled cyst with a small contrast-enhancing nodule in the wall, which is quite specific for hemangioblastoma. Solid tumors show intense contrast enhancement. 2) Complete blood count - shows elevated red blood cells (polycythemia). 3) VHL screening - especially if young age, multiple tumors, or family history: genetic testing, abdominal imaging (kidneys-pancreas), ophthalmologic examination, and complete spinal cord MRI. 4) Vascular imaging (angiography) - to identify feeding vessels before surgery. Definitive diagnosis is made by pathological examination after surgery.

VHL is a hereditary genetic disorder (can be passed from parents). Some cases of hemangioblastoma have associated VHL disease. In VHL patients, multiple hemangioblastomas can appear at a young age. This disease can also feature vascular tumors in the eye, kidney tumor risk, kidney and pancreatic cysts, adrenal gland tumors, and pancreatic tumors. Diagnosis is made by evaluating family history and associated tumors together. VHL patients are advised to have genetic counseling and family screening. Close follow-up is mandatory in these patients: annual MRI, abdominal imaging, and ophthalmologic examination.

Surgical approach varies by location: for cerebellar tumors, accessed through the back of the head; for spinal cord tumors, accessed by opening part of the vertebral bone. Preoperative embolization of feeding vessels can reduce bleeding risk. The tumor is removed as a single piece under the microscope. In cystic tumors, only the tumor nodule is removed, not the cyst wall. Possible risks: cerebellar-related speech and balance problems, cranial nerve involvement (especially in brainstem-adjacent tumors), cerebrospinal fluid leak, infection, and bleeding. Risk is low in experienced centers. Prognosis is usually very good when the tumor is completely removed.

Polycythemia is an increase in red blood cells in the blood and occurs in some cases of hemangioblastoma. The cause is that the tumor secretes a hormone that stimulates blood production (erythropoietin); this hormone stimulates bone marrow to increase red blood cell production. Symptoms include: facial flushing, headache, dizziness, itching, fatigue, and risk of thrombosis (stroke, heart attack). Treatment: when the tumor is completely removed, hormone secretion stops and polycythemia resolves within weeks-months. If polycythemia is present before surgery, phlebotomy or cytapheresis may be performed to reduce clotting risk.

The prognosis is usually very good. When the tumor is completely removed, most patients do not experience recurrence; if part of the tumor remains, recurrence risk increases. In single-tumor (sporadic) cases, most patients recover after complete removal. In cases with VHL disease, multiple tumors may be present, requiring repeat surgeries, but long-term survival is high in these patients as well. Recurrence usually occurs at or near the surgical site. MRI follow-up is more frequent in the first year, then annual. VHL patients require lifelong annual comprehensive screening (brain, spinal cord, abdominal MRI, and ophthalmologic examination).

No, because hemangioblastoma is a benign tumor, standard radiation or drug therapy is not usually used. The primary treatment is complete surgical removal. However, focused radiation therapy (Gamma Knife) may be an option in specific situations: 1) Deep-seated tumors not accessible by surgery (such as brainstem), 2) Patients with very high surgical risk, 3) Multiple small tumors in VHL patients where selected tumors are treated. In focused radiation therapy, tumor growth usually stops, but complete shrinkage is rare. Drug therapies are not effective for this tumor.

Yes, spinal cord hemangioblastoma surgery is technically more difficult. The tumor usually lies within the spinal cord and careful dissection from spinal cord tissue is a delicate procedure. Part of the vertebral bone is opened, the membrane surrounding the spinal cord is opened, and the tumor is carefully removed under the microscope. Complication risk is higher: spinal cord injury, arm-leg weakness, loss of sensation, and neuropathic pain (most are temporary, some may be permanent). Post-surgical deficits usually improve within months. Intraoperative neuromonitoring is important. When the tumor is completely removed, prognosis is usually good. Multiple spinal cord tumors are common in VHL patients.

Follow-up varies depending on whether the tumor is single or associated with VHL disease: 1) In single-tumor (sporadic) cases: post-operative control MRI, then more frequent in the first year, then annual MRI. If no recurrence, follow-up can be reduced. 2) In cases with VHL disease: lifelong annual follow-up is mandatory - complete brain and spinal cord MRI, abdominal imaging (kidneys-pancreas), ophthalmologic examination, adrenal gland tumor screening, and blood count. If a new tumor is detected, surgery is considered. VHL patients are advised to have genetic counseling and family screening; first-degree relatives should be screened from a specific age.